These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35573045)

  • 1. MSD-based assays facilitate a rapid and quantitative serostatus profiling for the presence of anti-AAV antibodies.
    Haar J; Blazevic D; Strobel B; Kreuz S; Michelfelder S
    Mol Ther Methods Clin Dev; 2022 Jun; 25():360-369. PubMed ID: 35573045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.
    Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C
    J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Pre-Existing Neutralizing Antibodies Against Adeno-Associated Virus Serotypes 1, 2, 5, 6, 8, and 9 in Sera of Different Pig Strains.
    Dai Y; Kavita U; Lampen MH; Gielen S; Banks G; Levesque P; Kozhich A; Pillutla R; Zhang Y; Jawa V; Adam L
    Hum Gene Ther; 2022 Apr; 33(7-8):451-459. PubMed ID: 34913759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction.
    Fitzpatrick Z; Leborgne C; Barbon E; Masat E; Ronzitti G; van Wittenberghe L; Vignaud A; Collaud F; Charles S; Simon Sola M; Jouen F; Boyer O; Mingozzi F
    Mol Ther Methods Clin Dev; 2018 Jun; 9():119-129. PubMed ID: 29766022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An investigation of the immune epitopes of adeno-associated virus capsid-derived peptides among hemophilia patients.
    Liu L; Xu B; Chen L; Liu J; Liu W; Xue F; Feng S; Jiang E; Han M; Shao W; Zhang L; Pei X
    Mol Ther Methods Clin Dev; 2024 Jun; 32(2):101245. PubMed ID: 38660620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence of Adeno-Associated Virus Neutralizing Antibodies in Males with Duchenne Muscular Dystrophy.
    Verma S; Nwosu SN; Razdan R; Upadhyayula SR; Phan HC; Koroma AA; Leguizamo I; Correa NS; Kuipa M; Lee D; Vanderford TH; Gardner MR
    Hum Gene Ther; 2023 May; 34(9-10):430-438. PubMed ID: 36324212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of Neutralizing Antibodies against Adeno-Associated Virus Serotypes 1, 2, and 9 in Non-Injected Latin American Patients with Heart Failure-ANVIAS Study.
    Sierra-Delgado JA; Likhite S; Bautista PK; Gómez-Ochoa SA; Echeverría LE; Guío E; Vargas C; Serrano NC; Meyer KC; Rincon MY
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid AAV-Neutralizing Antibody Determination with a Cell-Binding Assay.
    Guo P; Zhang J; Chrzanowski M; Huang J; Chew H; Firrman JA; Sang N; Diao Y; Xiao W
    Mol Ther Methods Clin Dev; 2019 Jun; 13():40-46. PubMed ID: 30623003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive
    Kruzik A; Koppensteiner H; Fetahagic D; Hartlieb B; Dorn S; Romeder-Finger S; Coulibaly S; Weber A; Hoellriegl W; Horling FM; Scheiflinger F; Reipert BM; de la Rosa M
    Hum Gene Ther Methods; 2019 Apr; 30(2):35-43. PubMed ID: 30734588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates.
    Kotterman MA; Yin L; Strazzeri JM; Flannery JG; Merigan WH; Schaffer DV
    Gene Ther; 2015 Feb; 22(2):116-26. PubMed ID: 25503696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
    Li P; Boenzli E; Hofmann-Lehmann R; Helfer-Hungerbuehler AK
    PLoS One; 2019; 14(3):e0212811. PubMed ID: 30897117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors.
    Kruzik A; Fetahagic D; Hartlieb B; Dorn S; Koppensteiner H; Horling FM; Scheiflinger F; Reipert BM; de la Rosa M
    Mol Ther Methods Clin Dev; 2019 Sep; 14():126-133. PubMed ID: 31338384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic and local immune responses to intraocular AAV vector administration in non-human primates.
    Ail D; Ren D; Brazhnikova E; Nouvel-Jaillard C; Bertin S; Mirashrafi SB; Fisson S; Dalkara D
    Mol Ther Methods Clin Dev; 2022 Mar; 24():306-316. PubMed ID: 35229004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
    Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes.
    Gardner MR; Mendes DE; Muniz CP; Martinez-Navio JM; Fuchs SP; Gao G; Desrosiers RC
    Mol Ther Methods Clin Dev; 2022 Mar; 24():199-206. PubMed ID: 35141348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.
    Leborgne C; Latournerie V; Boutin S; Desgue D; Quéré A; Pignot E; Collaud F; Charles S; Simon Sola M; Masat E; Jouen F; Boyer O; Masurier C; Mingozzi F; Veron P
    Cell Immunol; 2019 Aug; 342():103780. PubMed ID: 29571923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful AAV8 readministration: Suppression of capsid-specific neutralizing antibodies by a combination treatment of bortezomib and CD20 mAb in a mouse model of Pompe disease.
    Choi SJ; Yi JS; Lim JA; Tedder TF; Koeberl DD; Jeck W; Desai AK; Rosenberg A; Sun B; Kishnani PS
    J Gene Med; 2023 Aug; 25(8):e3509. PubMed ID: 36994804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of AAV Variants with Human Hepatocyte Tropism and Neutralizing Antibody Escape Capacity.
    Pei X; Shao W; Xing A; Askew C; Chen X; Cui C; Abajas YL; Gerber DA; Merricks EP; Nichols TC; Li W; Samulski RJ; Li C
    Mol Ther Methods Clin Dev; 2020 Sep; 18():259-268. PubMed ID: 32637455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.
    Boutin S; Monteilhet V; Veron P; Leborgne C; Benveniste O; Montus MF; Masurier C
    Hum Gene Ther; 2010 Jun; 21(6):704-12. PubMed ID: 20095819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort.
    Perocheau DP; Cunningham S; Lee J; Antinao Diaz J; Waddington SN; Gilmour K; Eaglestone S; Lisowski L; Thrasher AJ; Alexander IE; Gissen P; Baruteau J
    Hum Gene Ther; 2019 Jan; 30(1):79-87. PubMed ID: 30027761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.